BRIDGEWATER, New Jersey,
October 7, 2015 /PRNewswire/ --
Valeritas Inc. announced today that for the second year in a row
it is a recipient of a Cardinal Health Supply Chain Excellence
Award. The 2015 award was presented this afternoon at
Cardinal's annual Business Partners Conference in Columbus,
Ohio.
Cardinal Health, Inc. (NYSE: CAH) is a $103
billion health care services company that improves the
cost-effectiveness of health care. Cardinal Health
provides pharmaceuticals and medical
products and services to more than 100,000 locations each day
and is also the industry-leading direct-to-home medical
supplies distributor.
Candidates for the Cardinal Health Supply Chain Excellence Award
were judged across a variety of metrics specifically targeted at
the importance of developing collaborative relationships with
manufacturers and providing exceptional service to each and every
one of Cardinal's valued business partners. Approximately 10%
of the 800 manufacturers eligible received awards.
"We are delighted to be recognized by Cardinal Health again this
year. Valeritas understands the Cardinal metrics and
habitually and reliably executes a very well organized and
professional working protocol consistently meeting Cardinal's
benchmarks and strict criteria. Valeritas is dedicated to being a
good partner, not only for patients but also for distributors who
stock and supply the V-Go® Disposable Insulin Delivery
Device. We look forward to continuing in this light and to
realizing additional future successes together," said Kristine Peterson, Chief Executive Officer of
Valeritas. "
Valeritas also announced today that it will continue to
participate on the Cardinal Health Supplier Advisory Board.
The company was invited to participate on the Board in 2013.
The Board, comprised of ten core members, makes
recommendations to Cardinal to improve supplier relations and
maintain high standards of achievement.
"Being part of the Cardinal Health Supplier Advisory Board is an
honor and a privilege as it affords an opportunity to actively
contribute to the further advancement of the industry and its
systems. Membership is also especially important for
Valeritas, as it supports V-Go®'s classification as a
branded product. Though V-Go® is a non-drug
device, it is treated as a branded pharmaceutical and is available
to patients at retail pharmacies. This is very unique, as
most medical devices are not available to patients at retail
pharmacies," said Kathy Lang, Senior
Director, Trade Relations at Valeritas and Member of the Cardinal
Health Supplier Advisory Board.
V-Go® is a simple, wearable, basal-bolus insulin
delivery solution for patients with diabetes that enables patients
to administer a continuous, preset basal rate of insulin over 24
hours and provides on demand bolus dosing at mealtimes with U-100
fast acting insulin.
About the V-Go® Disposable Insulin
Delivery Device
V-Go® is a small, discreet, wearable and easy-to-use
disposable insulin delivery solution for the delivery of
basal-bolus insulin therapy in adults with Type 2 diabetes.
V-Go® enables patients to closely mimic the body's
normal physiologic pattern of insulin delivery by releasing a
single type of insulin at a continuous preset basal rate over a
24-hour period and also providing for on-demand bolus dosing at
mealtimes. V-Go® is mechanical and operates for 24 hours
without electronics, batteries, infusion sets or programming. It is
worn on the skin under clothing and measures just 2.4 inches wide
by 1.3 inches long by 0.5 inches thick, weighing approximately one
ounce when filled with insulin.
Important Risk Information: If regular adjustments or
modifications to the basal rate of insulin are required in a
24-hour period, or if the amount of insulin used at meals requires
adjustments of less than 2-Unit increments, use of the
V-Go® Disposable Insulin Delivery Device may result in
hypoglycemia. The following conditions may occur during insulin
therapy with V-Go®: hypoglycemia (low blood glucose) or
hyperglycemia (high blood glucose). Other adverse reactions
associated with V-Go® use include skin irritation from
the adhesive pad or infections at the infusion site. V-Go should be
removed before any magnetic resonance imaging (MRI) testing.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused
on developing innovative technologies to improve the health and
quality of life of people with Type 2 diabetes. Valeritas' flagship
product, the V-Go®, is the first, simple, wearable,
basal-bolus insulin delivery solution for patients with Type 2
diabetes that enables patients to administer a physiological,
continuous, preset basal (continuous) rate infusion of insulin over
24 hours. It also provides on demand bolus dosing at mealtimes.
It is the only basal bolus insulin delivery system on the
market today specifically designed keeping in mind the needs of
type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates
its R&D functions in a state-of-the-art facility in
Shrewsbury, Massachusetts. For
more information, please visit http://www.valeritas.com.
Press Contact:
Marjie Hadad
MH Communications
marjierhadad@gmail.com
+1-908-947-0378
SOURCE Valeritas Inc.